Ibrutinib-associated osteonecrosis of the jaw by Annu Singh, Sion Na, Joseph M. Huryn, Cherry L. Estilo, Steven Horwitz, SaeHee K. Yom

Subjects: Get full text

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver by Indra Radek, Jelínková Sandra, Kollárová Katarína, Zahumenská Petra, Dvořák Josef, Dušková Šárka, Dračínská Helena

Subjects: Get full text

Vitiligo-like lesions following imatinib mesylate therapy: a case series and review of literature by Neerja Saraswat, Shekhar Neema, Sushil Kumar

Subjects: Get full text

Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial by Liu Y, Li X, Zhang M, Men Y, Wang Y, Zhu X, Zheng L

Subjects: Get full text

Prognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma by Dan Liu, Xia Yin, Hui Wang, Lijie Xing, Ping Li, Haichen Wei, Ji Ma, Qiang He, Linna Xie, Ke Lu, Zengjun Li

Subjects: Get full text

Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases by Nozomi Sasaki, Yukiko Enomoto, Takamitsu Hori, Hirofumi Matsubara, Yusuke Egashira, Tsuyoshi Izumo

Subjects: Get full text

Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations by Masato Kikuta, Sei Naito, Takahiro Osawa, Kazuyuki Numakura, Takafumi Narisawa, Yuki Takai, Mayu Yagi, Yuya Sekine, Ojiro Tokairin, Nobuo Shinohara, Tomonori Habuchi, Norihiko Tsuchiya

Subjects: “…Renal cell carcinoma; Tyrosine kinase inhibitor…”
Get full text

Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors? by Cristina Maria Failla, Maria Luigia Carbone, Carmela Ramondino, Emanuele Bruni, Angela Orecchia

Subjects: Get full text

Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II by Hu Jiaming, Zhang Minghui, Liu Huiqiang, Zhang Zongli, Xu Yunfei

Subjects: Get full text

Assessment of efficacy and safety of imatinib as an adjunct host-targeted therapy for parasite clearance in chloroquine-resistant malaria: a prospective case control study by Fazeel Zubair Ahmed, Shaifulla P

Subjects: Get full text

RESULTS OF CLINICAL TRIALS OF MEDICAL TREA TMENT OF RENAL CELL CARCINOMA IN 2014–2015 by A. M. Popov, O. B. Karyakin, A. D. Kaprin

Subjects: Get full text

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors by Ichiro Yamauchi, Daisuke Yabe

Subjects: Get full text

Solid lipid nanoparticles for increased oral bioavailability of acalabrutinib in chronic lymphocytic leukaemia by Swagata Sinha, Punna Rao Ravi, Makarand Somvanshi, S. R. Rashmi

Subjects: “…Tyrosine kinase inhibitor…”
Get full text

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis o... by Kei Sonehara, Kazunari Tateishi, Kiyotaka Yoh, Kazuhiro Usui, Yukio Hosomi, Kazuma Kishi, Go Naka, Kageaki Watanabe, Shu Tamano, Kohei Uemura, Hideo Kunitoh

Subjects: Get full text

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial by Xiaoyang Hong, Yongjian Guo, Wenbo Shi, Kangshun Zhu, Licong Liang, Liteng Lin, Ye Chen, Jingwen Zhou, Jingjun Huang, Jiabai Huang, Yaozhu Wu, Wensou Huang, Mingyue Cai

Subjects: Get full text

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute... by Xiaoxia Wu, Shenqi Lu, Xinhui Zhang, Zhen Yang, Aining Sun, Depei Wu, Huifen Zhou, Miao Miao

Subjects: Get full text

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors by Russell J. Schilder, Drew Rasco, Manish R. Sharma

Subjects: Get full text

Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study by Chenming Liu, Jintao Chen, Yuxing Liu

Subjects: “…Tyrosine kinase inhibitor…”
Get full text

Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Ad... by Yan-Jei Tang, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu

Subjects: Get full text

Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients by Piyada Sitthideatphaiboon, Pronwasun Simseekeaw, Chinachote Teerapakpinyo, Nicha Zungsontiporn, Wariya Chintanapakdee, Itthi Itthisawatpan, Shanop Shuangshoti, Virote Sriuranpong, Thanisa Tongbai, Chanida Vinayanuwattikun

Subjects: Get full text